key: cord-0771335-vu5ppifg
authors: Patel, Shailesh Kumar; Saikumar, Gutulla; Rana, Jigyasa; Dhama, Jaideep; Yatoo, Mohd Iqbal; Tiwari, Ruchi; Rodríguez-Morales, Alfonso J.; Dhama, Kuldeep
title: Dexamethasone: A boon for critically ill COVID-19 patients?
date: 2020-08-10
journal: Travel Med Infect Dis
DOI: 10.1016/j.tmaid.2020.101844
sha: 0a81bdb1ec55d0a6fd1c610b85ce7b4ba4f280e4
doc_id: 771335
cord_uid: vu5ppifg

nan

As observed at the beginning of other coronaviruses epidemics, such as SARS in 2002 and MERS in 2012 [1] , the search of therapeutic interventions has been intense for the coronavirus disease 2019 . The absence of an effective vaccine, treatment regimen, and managemental guidelines for COVID-19 has been responsible for rapid spread and heavy death toll. The COVID-19 associated mortalities in severe forms were mainly attributed to respiratory failure, probably due to lethal pneumonia caused by rampant inflammation [2] . The SARS-CoV-RECOVERY trial, a randomized, controlled, and open-label trial has begun in March 2020 and aimed to investigate several potential COVID-19 treatments on hospitalized patients [3] .

Moreover, dexamethasone has been proven to significantly reduce the mortality risk in COVID-19 patients on ventilation and oxygen by as much as 35% and 20%, respectively. After that, the dexamethasone has been authorized by the UK government for the treatment of critically ill COVID-19 patients. However, no clinical benefits were seen in patients with mild, moderate, and hospitalized COVID-19 patients, not on oxygen or ventilation [4] .

The dexamethasone (synthetic pregnane corticosteroid; a cortisol derivative) is a well-known lifesaving drug and commonly used to treat inflammatory and autoimmune conditions ( Figure 1 ).

It is widely used for the treatment and management of rheumatic problems, skin diseases, asthma, many forms of allergies, chronic obstructive lung disease, brain edema, eye pain, as a result of eye surgery and bronchospasm. The mechanism of action of corticosteroids is diverse, with many effects on various body systems. The corticosteroids inhibit the action and expression of many molecules involved in pneumonia associated inflammatory response. Moreover, many molecular mechanisms are associated with corticosteroids and include transactivation by increasing the gene transcription of different anti-inflammatory cytokines [5] .

Additionally, the corticosteroids may induce trans-expression by decreasing gene transcription of various pro-inflammatory cytokines, chemokines, and adhesion molecules [5] . Moreover, experimental studies revealed a reduced inflammatory response after the administration of corticosteroid in severe community-acquired pneumonia [6] . In this context, the antiinflammatory effect of the dexamethasone is suggested to probably counter the cytokine storm https://www.irct.ir/) has already been launched to test the hypothesis of whether early administration of dexamethasone along with IV-IG and IFN-β can reduce the harmful effects of cytokine storm in critically ill COVID-19 patients or not. Moreover, dexamethasone is approved by the FDA as a broad-spectrum immunosuppressant and reported to be about 30 times more active than cortisone with an added advantage of longer duration of action. Furthermore, dexamethasone is suggested to limit the production of inflammatory cytokines and their damaging effect. However, inhibition of T cells functions and blockage of B cells from making immunoglobulins may potentially lead to an increase in plasma viral load, which is a primary concern and needs further investigation [6] .

The breakthrough discovery of dexamethasone as the first drug to save lives is very encouraging.

It enlightens the hope to reduce the mortality in critically ill hospitalized patients. Though the drug is found to be effective in only patients on ventilators or oxygen, the overall impact on reducing the mortality will be huge because critically ill patients are the great contributors to the COVID-19 death toll. Furthermore, the comparatively low price and worldwide availability of the drug will contribute to the reduction worries caused by the pandemic. The drug will prove a boon for low and middle-income countries where an effective but expensive drug would be J o u r n a l P r e -p r o o f

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

Anti-inflammatory action of glucocorticoids--new mechanisms for old drugs

Effects of glucocorticoids in ventilated piglets with severe pneumonia

We declare that we have no competing interests.Credit. SKP, Conceptualization; Writing -review & editing. Rest of the authors, Writing -review & editing.